Arcus Biosciences (RCUS) Receivables - Other (2017 - 2026)

Arcus Biosciences' Receivables - Other history runs 10 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 73.33% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 73.33% decrease from a year earlier, with the FY2025 full-year figure at $11.0 million, down 45.0% from the prior year.
• Receivables - Other declined to $4.0 million in Q1 2026 per RCUS's latest filing, from $11.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $52.0 million in Q3 2023 and bottomed at $4.0 million in Q1 2026.
• The 5-year median for Receivables - Other is $28.0 million (2024), against an average of $25.9 million.
• Biggest YoY gain for Receivables - Other was 2944.89% in 2022; the steepest drop was 94.77% in 2022.
• Year by year, Receivables - Other stood at $39.0 million in 2022, then declined by 2.56% to $38.0 million in 2023, then sank by 47.37% to $20.0 million in 2024, then sank by 45.0% to $11.0 million in 2025, then tumbled by 63.64% to $4.0 million in 2026.
• Per Business Quant, the three latest RCUS Receivables - Other figures stand at $4.0 million (Q1 2026), $11.0 million (Q4 2025), and $11.0 million (Q3 2025).